ClinicalTrials.gg
Not yet recruitingNCT07376330Updated Nov 12, 2026

Molecular and Cellular Characterization of MALT Lymphoma

An observational study in MALT Lymphoma, sponsored by International Extranodal Lymphoma Study Group (IELSG). Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by International Extranodal Lymphoma Study Group (IELSG) · Observational

How we know

Updated Nov 12, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Lymphoma, B-Cell, Marginal Zone by International Extranodal Lymphoma Study Group (IELSG) — 2 open to participants now, 6 under way, none of them phase 3. Lymphoma, B-Cell, Marginal Zone · International Extranodal Lymphoma Study Group (IELSG).

Started
2027
the only one that year
Observational
3 of 12
2 open now
Registered
12th of 12
by date

Among the 12 studies in Lymphoma, B-Cell, Marginal Zone by International Extranodal Lymphoma Study Group (IELSG), this one is the only one that started in 2027, is one of 3 observational ones, and was the 12th registered.

Lymphoma, B-Cell, Marginal Zone

877 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 113 are open to participants now.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Open to participants now

2 of the 12 studies in Lymphoma, B-Cell, Marginal Zone by International Extranodal Lymphoma Study Group (IELSG) are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 93 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 78 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lymphoma, B-Cell, Marginal Zone by International Extranodal Lymphoma Study Group (IELSG), or all of them as a file.
02

Study summary

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is an slow growing malignancy characterized by marked biological and clinical differences across different anatomical sites.

Using participants' samples and clinical information, this observational and non-interventional research aims to generate a comprehensive molecular and cellular atlas of MALT lymphoma. The results will enable the identification of biologically meaningful tumor subtypes, microenvironmental niches, and candidate biomarkers with potential relevance for the diagnosis, prognosis, and therapy of MALT lymphoma.

Read the detailed description

Already existing and coded tumor biological material and health-related patient data will be retrospectively collected from institutional biobanks and patients' charts or electronic medical records upon receipt of ethical approval. Each patient enrolled in the study will be assigned a unique identification numerical code upon registration in the study. The unique identification code will be used to record health-related data and to label biological samples. The coded biological material will be transferred to the coordinating center at the Institute of Oncology Research (IOR) in Bellinzona. Health-related data will be collected in the electronic case report form (eCRF) (OpenClinica). Data quality will be ensured by query generation.

Annotated baseline features will include the date of diagnosis, date of biopsy, age, gender, Eastern Cooperative Oncology Group Performance Status (ECOG PS), Ann Arbor stage, lactate dehydrogenase (LDH), number and location of extranodal sites, bone marrow involvement and percentage, peripheral blood involvement, number of nodal sites, B symptoms, lymph nodes larger than 7 cm, hemoglobin (Hb), platelets, lymphocytes, beta-2-microglobulin, albumin, infections (hepatitis C virus, Helicobacter pylori, Chlamydophila psittaci, Achromobacter xylosoxidans, Campylobacter jejuni), serum paraprotein presence and type.

Annotated follow-up features included the date of progression to a disease requiring treatment, type of first-line treatment, date of start of the first line treatment, date of progression after first line treatment, date of the second line treatment, type of second line treatment, date of transformation, date of death, cause of death, and date of last follow-up. Mutation analysis, immunoglobulin genes and T cell receptor rearrangement analysis, copy number aberration analysis, structural variant analysis, and deoxyribonucleic acid (DNA) methylation profile will be performed by next-generation sequencing of genomic DNA extracted from the biopsy. Gene expression will be assessed by next-generation sequencing of RNA extracted from the biopsy. Protein expression will be assessed by mass spectrometry of proteins extracted from the biopsy. AI-based computational pathology will be performed on digitized whole-slide images of the biopsy to extract quantitative histologic features.

Single-cell transcriptomic profiling will be used to resolve intratumoral heterogeneity and to define malignant and non-malignant cellular populations. After quality control, normalization, and batch correction, unsupervised clustering will be applied to identify transcriptionally distinct cell states. Malignant B-cell populations will be distinguished from reactive B cells using a combination of copy number inference, immunoglobulin expression patterns, and canonical marker genes. Differential expression and pathway enrichment analyses will be conducted to identify signaling programs associated with anatomical site, immune context, and disease features.

In details:

  • Spatial transcriptomics and/or spatial proteomics will be employed to preserve tissue architecture and assess the spatial organization of tumor cells, immune infiltrates, and stromal components. Spatial domains and cellular neighborhoods will be identified using data-driven segmentation and neighborhood analysis approaches. Spatial co-localization and interaction analyses will be used to infer tumor-microenvironment crosstalk, immune exclusion or activation niches, and site-specific spatial patterns that may influence therapeutic response.
  • Immune repertoire profiling (BCR/TCR sequencing) will be integrated, where available, to assess clonality, antigen-driven selection, and spatial distribution of immune clones. In malignant B cells, immunoglobulin features will be used to explore evidence of antigen dependence and ongoing selection, while TCR diversity and expansion will be evaluated in relation to immune niches and tumor proximity.
  • Proteomic and/or epigenetic data, when available, will be incorporated to refine functional interpretation of transcriptional programs and to identify post-transcriptional or regulatory mechanisms underlying observed cellular states.

Cross-modal integration will be performed using established computational frameworks to generate unified cell state annotations and pathway activity scores. Comparative analyses across anatomical sites will be a central assessment. Conserved versus site-specific cellular states, immune compositions, and signaling pathways will be systematically evaluated to identify shared disease mechanisms as well as context-dependent features. Associations with clinical variables (e.g., site of origin, prior treatment, disease stage) will be explored in an exploratory, hypothesis-generating manner.

All analyses will follow reproducible computational workflows with stringent quality control, appropriate correction for technical confounders, and transparent reporting of limitations. The resulting datasets and analytical outputs will provide an integrated molecular and spatial reference framework for MALT lymphoma, supporting downstream biomarker discovery and future translational studies.

03

Conditions studied

  • MALT Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients with diagnosis of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue on histology after Jan 1st, 2000

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adults 18 years or older
  2. Diagnosis of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue on histology after Jan 1st, 2000.
  3. Availability of tumor material from (either frozen or formalin-fixed paraffin-embedded) (FFPE).
  4. Availability of the baseline and follow-up annotations.

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
400 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Molecular and spatial profiles of MALT lymphoma

    Generation of high-resolution molecular and spatial profiles of MALT lymphoma tissues, including annotation of malignant and non-malignant cell populations.

    Time frame: 6 months: from the end of samples collection to the end of study analysis

Secondary outcomes

  1. Creation of a curated multi-omics dataset

    Identification of spatial tumor-immune interactions, characterization of BCR/TCR clonality, derivation of molecular signatures associated with anatomical site and microenvironment, and creation of a curated multi-omics dataset suitable for deposition in controlled-access repositories

    Time frame: 6 months: from the end of samples collection to the end of study analysis

  2. Extraction of clinically relevant features using artificial intelligence (AI) from histology sections

    Time frame: 6 months: from the end of samples collection to the end of study analysis

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Processed molecular data, including single-cell and spatial transcriptomic matrices, cell type annotations, and derived pathway activity scores, will be made available to the scientific community through established public repositories (e.g. GEO, ArrayExpress, or Zenodo), such as controlled-access archives for human genomics data, once primary analyses and initial publications are completed.

Supporting information: Study protocol, Clinical study report

Time frame: From March 2029 to March 2035

Access criteria: Raw sequencing data will be deposited where permitted by consent and regulatory frameworks or otherwise shared in controlled-access form to qualified researchers upon reasonable request. Analysis code, computational workflows, and documentation will be shared via publicly accessible version-controlled repositories to ensure transparency and reproducibility

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Apr 2027; primary completion for Dec 2029, 32 months later.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Apr 2027, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Jan 29, 2026
StartEst.
Apr 1, 2027was Sep 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Apr 1, 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Start date Sep 2026→Apr 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07376330
Lead sponsor
International Extranodal Lymphoma Study Group (IELSG)
Responsible party
Sponsor
First posted
Jan 29, 2026
Start date
Apr 1, 2027 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

International Extranodal Lymphoma Study Group - IELSG
Contact
ielsg@ior.usi.ch
+41 58 666 7321
Luciano Cascione, PhD
study chair · Foundation for the Institute of Oncology Research
Francesco Bertoni, MD
study chair · Foundation for the Institute of Oncology Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion